Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|August 2, 2022

Dr. Khetrapal discusses intracorporeal robotic vs open cystectomy

Author(s)Urology Times staff

Pramit Khetrapal, MD, academic clinical fellow in Urology, Barts Health NHS Trust compares intracorporeal robot-assisted radical cystectomy (iRARC) with open RC. At the 2022 AUA Annual Meeting, Khetrapal presented the abstract, “Results of the intracorporeal robotic vs open cystectomy (IROC) multi-centre randomised trial.”

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

KEYNOTE-B15 data on enfortumab vedotin plus pembrolizumab in MIBC published in NEJM

ByHannah Clarke

July 23rd 2026

Improving CIS detection: Diagnostic tools and the urologist–pathologist relationship

ByArpeet Shah, MD,Prithvi Murthy, MD,Kenneth Beck, MD

July 22nd 2026

Experts discuss the challenge of detecting CIS in bladder cancer

ByArpeet Shah, MD,Prithvi Murthy, MD,Kenneth Beck, MD

July 21st 2026

Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC

ByTyler Garman, MD

July 21st 2026

Kathryn Gessner, MD, PhD, on the challenges of selecting patients for bladder preservation

ByKate Gessner, MD, PhD

July 20th 2026

Latest CME

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

FDA grants tentative approval to generic olaparib tablets across previously approved indications

Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC

Published data support PSMA-PET–guided selection for 177Lu-rosopatamab tetraxetan in mCRPC

Prof Declan Murphy on interpreting the PROTEUS trial in localized prostate cancer

Improving CIS detection: Diagnostic tools and the urologist–pathologist relationship